Myriad Genetics, Inc. (NASDAQ:MYGN – Get Free Report) Director Daniel K. Spiegelman sold 3,788 shares of the firm’s stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $22.04, for a total value of $83,487.52. Following the completion of the transaction, the director now owns 36,705 shares of the company’s stock, valued at approximately $808,978.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Myriad Genetics Stock Down 0.0 %
Shares of Myriad Genetics stock traded down $0.01 during trading on Tuesday, hitting $22.34. 828,642 shares of the stock traded hands, compared to its average volume of 686,591. The company has a fifty day moving average price of $21.37 and a two-hundred day moving average price of $20.94. Myriad Genetics, Inc. has a twelve month low of $13.82 and a twelve month high of $25.95. The stock has a market cap of $2.02 billion, a P/E ratio of -7.96 and a beta of 1.95. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.82 and a current ratio of 1.99.
Myriad Genetics (NASDAQ:MYGN – Get Free Report) last issued its quarterly earnings data on Tuesday, May 7th. The company reported ($0.01) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.09. Myriad Genetics had a negative net margin of 30.30% and a negative return on equity of 6.77%. The firm had revenue of $202.20 million during the quarter, compared to analysts’ expectations of $193.51 million. During the same period in the prior year, the company posted ($0.28) earnings per share. Myriad Genetics’s revenue for the quarter was up 11.6% on a year-over-year basis. Equities research analysts predict that Myriad Genetics, Inc. will post -0.35 EPS for the current fiscal year.
Hedge Funds Weigh In On Myriad Genetics
Several large investors have recently made changes to their positions in the business. Victory Capital Management Inc. boosted its position in Myriad Genetics by 1.5% in the third quarter. Victory Capital Management Inc. now owns 60,201 shares of the company’s stock valued at $966,000 after buying an additional 912 shares in the last quarter. Barclays PLC grew its holdings in shares of Myriad Genetics by 10.1% in the 3rd quarter. Barclays PLC now owns 142,372 shares of the company’s stock valued at $2,283,000 after buying an additional 13,068 shares during the period. Swiss National Bank increased its holdings in shares of Myriad Genetics by 1.0% in the third quarter. Swiss National Bank now owns 179,300 shares of the company’s stock worth $2,876,000 after acquiring an additional 1,800 shares in the last quarter. Charles Schwab Investment Management Inc. increased its stake in Myriad Genetics by 2.9% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 884,806 shares of the company’s stock worth $14,192,000 after purchasing an additional 24,665 shares in the last quarter. Finally, Citigroup Inc. raised its holdings in Myriad Genetics by 5.0% during the 3rd quarter. Citigroup Inc. now owns 121,780 shares of the company’s stock worth $1,953,000 after buying an additional 5,799 shares during the period. Institutional investors and hedge funds own 99.02% of the company’s stock.
Wall Street Analyst Weigh In
Several research firms have recently weighed in on MYGN. Leerink Partnrs raised Myriad Genetics from a “market perform” rating to an “outperform” rating in a research note on Wednesday, May 8th. Piper Sandler boosted their price target on Myriad Genetics from $23.00 to $28.00 and gave the stock a “neutral” rating in a research note on Monday, May 13th. Jefferies Financial Group restated an “underperform” rating and set a $20.00 price objective (down previously from $25.00) on shares of Myriad Genetics in a research note on Monday. Finally, SVB Leerink raised shares of Myriad Genetics from a “market perform” rating to an “outperform” rating and raised their price target for the stock from $25.00 to $35.00 in a research report on Wednesday, May 8th. Two analysts have rated the stock with a sell rating, three have issued a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $24.88.
Myriad Genetics Company Profile
Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women’s and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.